Threshold Pharmaceuticals Appoints Laura G. Hansen, Ph.D., Senior Director, Corporate Communications

Threshold Pharmaceuticals, Inc.

today announced the appointment of Laura G. Hansen, Ph.D., as Senior Director, Corporate Communications. In this role, Dr. Hansen is responsible for heading investor and public relations functions. Dr. Hansen brings to Threshold 13 years of experience in corporate communications and investor relations in the biotechnology industry. She most recently served as Director, Corporate Communications at FibroGen, Inc., a privately held, development stage biotechnology company. Prior to that, she was Director, Corporate Communications and Investor Relations at Corvas International, Inc. (acquired by Dendreon Corporation). Dr. Hansen began her career in communications at Susan E. Atkins + Associates (acquired by Porter Novelli), an investor and public relations agency focused solely on the biotechnology industry. Dr. Hansen holds a B.S. in Zoology and Ph.D. in Biological Sciences from the University of Texas at Austin.